Rat Nogo-A aa 2-172 Antibody
R&D Systems, part of Bio-Techne | Catalog # AF3098
Scientific images may be resized, cropped, or adjusted for brightness or contrast for presentation purposes. These updates are limited to presentation and do not affect the underlying scientific interpretation of the data. Where available, additional source data may be provided upon request.
Conjugate
Catalog #
Key Product Details
Validated by
Biological Validation
Species Reactivity
Validated:
Rat
Cited:
Human, Mouse, Rat
Applications
Validated:
Immunohistochemistry, Western Blot
Cited:
Immunohistochemistry, Western Blot
Label
Unconjugated
Antibody Source
Polyclonal Goat IgG
Product Specifications
Immunogen
E. coli-derived recombinant rat Nogo-A
Glu2-Val172
Accession # Q9JK11
Glu2-Val172
Accession # Q9JK11
Specificity
Detects rat Nogo-A in direct ELISAs and Western blots.
Clonality
Polyclonal
Host
Goat
Isotype
IgG
Scientific Data Images for Rat Nogo-A aa 2-172 Antibody
Detection of Rat Nogo-A by Western Blot
RT-PCR analysis and western blot analysis of Nogo-A mRNA and protein production in the hippocampus after TBI. (A) The PCR products from Nogo-A transcription after TBI with the yield of actin as an internal control. The sampling times after TBI are shown on the top (n = 4 in each group). (B) Quantification of Nogo-A mRNA expression by semiquantitative densitometry in conjunction with AlphaEase software (Alpha Innotech Corp.). (C) Time course of Nogo-A protein production after TBI, internal control: beta-actin. Times shown on top represent hours after injury. (D) Quantification of Nogo-A protein by semiquantitative densitometry in conjunction with AlphaEase software (Alpha Innotech Corp.). The data are presented as ratios related to the sham group. Bars represent the means ± SEM values. *p < 0.05 is considered significantly different from sham values using the Mann–Whitney U test. SEM, standard error of the mean; TBI, traumatic brain injury. Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094…), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Rat Nogo-A by Western Blot
Effects of Nogo-A irrelevant control and antisense oligodeoxynucleotides on hippocampal Nogo-A expression after TBI. (A) RT-PCR analysis of Nogo-A mRNA transcription level. Actin transcription was used as an internal control. (B) The expression of Nogo-A was quantified by densitometry and compared with the data from rats injected with saline (sham), which was normalized to 100%. (C) Western blot analysis of Nogo-A protein level; beta-actin was used as an internal control. (D) Quantification of Nogo-A protein by semiquantitative densitometry in conjunction with AlphaEase software (Alpha Innotech Corp.). The data are presented compared with the sham group. The data are represented as the means ± SEM values (n = 6). *p < 0.05 was considered significantly different from the sham value using the Mann-Whiney U test, and #p < 0.05 was considered significantly different from the TBI with sense values using the Mann-Whiney U test. SEM, standard error of the mean; TBI, traumatic brain injury. Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094…), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Rat Nogo-A by Western Blot
Effects of indomethacin administration on Nogo-A expression. Animals were in one of four groups: sham (no TBI), TBI treatment (TBI eight hours), TBI combined with vehicle administration (TBI + vehicle), and TBI combined with indomethacin administration (TBI + indomethacin). (A) RT-PCR analysis of the expression of Nogo-A among different groups along with the analysis of beta-actin transcription as an internal control. (B) Quantification of Nogo-A expression. (C) Western blot analysis of the expression of Nogo-A among different groups along with the analysis of beta-actin as an internal control. (D) Quantification of Nogo-A expression. Bars represent means ± SEM values (n = 5). *P <0.05 is considered significantly different from the sham value using the Mann–Whitney U test and #P <0.05 is considered significantly different from the TBI value using the Mann–Whitney U test. SEM, standard error of the mean; TBI, traumatic brain injury. Image collected and cropped by CiteAb from the following publication (https://jneuroinflammation.biomedcentral.com/articles/10.1186/1742-2094…), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Rat Nogo-A aa 2-172 Antibody
Application
Recommended Usage
Immunohistochemistry
5-15 µg/mL
Sample: Perfusion fixed frozen sections of rat brain (caudate putamen)
Sample: Perfusion fixed frozen sections of rat brain (caudate putamen)
Western Blot
0.1 µg/mL
Sample: Recombinant Rat Nogo-A Fc Chimera (Catalog # 2445-NG)
Sample: Recombinant Rat Nogo-A Fc Chimera (Catalog # 2445-NG)
Formulation, Preparation, and Storage
Purification
Antigen Affinity-purified
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
Shipping
Lyophilized product is shipped at ambient temperature. Liquid small pack size (-SP) is shipped with polar packs. Upon receipt, store immediately at the temperature recommended below.
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: Nogo-A
Long Name
Reticulon 4A
Alternate Names
NI220, NogoA, RTN4, RTN4A
Gene Symbol
RTN4
UniProt
Additional Nogo-A Products
Product Documents for Rat Nogo-A aa 2-172 Antibody
Product Specific Notices for Rat Nogo-A aa 2-172 Antibody
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...